PharmAthene, Inc., a biodefense company, engages in the development and commercialization of medical countermeasures against biological and chemical threats in the United States. Its product candidates include SparVax, a recombinant protective antigen anthrax vaccine that has completed a Phase IIb clinical trial for post-exposure prophylaxis in conjunction with antibiotics and general use prophylaxis; Valortim, a human monoclonal antibody, which has completed a Phase I clinical trial for the prevention and treatment of anthrax infection; and rBChE (recombinant butyrylcholinesterase) bioscavanger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides. The company primarily serves the United States Department of Defense, Chemical Biological Medical Systems, the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, and the National Institute of Health. It has a collaboration agreement with Bristol Myers Squibb, Inc. for the development of Valortim. The company was founded in 2001 and is headquartered in Annapolis, Maryland.

Key Statistics